Upstream Biosciences to initiate efficacy testing for Leishmaniasis treatment
Joel Bellenson, CEO of Upstream, said the animal testing may determine whether one or more of the drug candidates have sufficient anti-parasitic activity to proceed down a path
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.